Stay updated with breaking news from Lupus Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Karen Costenbader, MD, discusses how early intervention with belimumab in patients with lupus significantly reduces disease flares and prevents irreversible organ damage.
Rates of significant disease reactivation were similar more than 1 year after randomization for patients assigned to mycophenolate mofetil (MMF) withdrawal or MMF maintenance.
/PRNewswire/ -- Lupus is a complicated and debilitating autoimmune disease, affecting millions of people across the globe. Yet, lupus drug development lags...
The American Autoimmune Related Disease Association (AARDA) hosted the 15th Noel Rose Scientific Colloquium on May 1, 2021, bringing together high-level researc
Read More "There is a lot about lupus that is still a conundrum to us," said Dr. Karen H. Costenbader, a professor of medicine at Harvard Medical School and director of the Lupus Program at Brigham and Women's Hospital in Boston. "It's treatable, but it can still be very painful and challenging to overcome," said Costenbader, who is also chair of the Lupus Foundation of America's Medical-Scientific Advisory Council. May 10 is World Lupus Day, and we recently caught up with Costenbader to learn more about the disease. This conversation has been edited and condensed for clarity. CNN: What does...